- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- GS-9450, GS-9450 Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • Fresno, California • Fullerton, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 572
matching trials from the live ClinicalTrials.gov search.
- Conditions
- NAFLD
- Interventions
- NAFLD-specific weight loss intervention, Wait-list control
- Behavioral · Other
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- NAFLD, NASH
- Interventions
- DD01, Placebo
- Drug
- Lead sponsor
- Neuraly, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Maitland, Florida • Monroe, Louisiana • West Monroe, Louisiana + 8 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- CS0159 (Linafexor)
- Drug
- Lead sponsor
- Cascade Pharmaceuticals, Inc
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 17
- States / cities
- Gardena, California • Huntington Park, California • Panorama City, California + 13 more
- Conditions
- End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
- Interventions
- Tocotrienol (TCT), Placebo
- Drug · Other
- Lead sponsor
- Chandan Sen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Fatty Liver
- Interventions
- Cysteamine
- Drug
- Lead sponsor
- Joel Lavine
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Interventions
- Magnetic Resonance Elastography, Blood draw, Liver biopsy, Fibro Scan
- Diagnostic Test · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Interventions
- DR cysteamine bitartrate capsule, DR cysteamine bitartrate placebo
- Drug · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 10
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 7 more
- Conditions
- NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
- Interventions
- ALG-055009, Placebo
- Drug
- Lead sponsor
- Aligos Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 40
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 37 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- TERN-201, Placebo
- Drug · Other
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more
- Conditions
- NAFLD
- Interventions
- Not listed
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hepatitis C Virus (HCV) Coinfection, Hepatitis B Virus (HBV), Drug-Induced Liver Injury
- Interventions
- Shear Wave Sonoelastography
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Liver Diseases
- Interventions
- Pioglitazone, Vitamin E, Matching placebo
- Drug · Dietary Supplement
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 8
- States / cities
- San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
- Interventions
- Not listed
- Lead sponsor
- OSF Healthcare System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Peoria, Illinois
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- GS-9674, Placebo to match GS-9674
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Rialto, California • Coral Gables, Florida + 19 more
- Conditions
- Nonalcoholic Steatohepatitis, Liver Fibrosis
- Interventions
- Synthroid, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Fluconazole, Quinidine, EDP-305
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Miricorilant, Placebo
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 11 more
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Survodutide, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 36
- States / cities
- Huntsville, Alabama • Coronado, California • Huntington Park, California + 31 more
- Conditions
- Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
- Interventions
- Lanifibranor, Placebo
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Liver Diseases
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 1,649 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 16
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 11 more
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- Dietary modification
- Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 11 Years to 16 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- San Diego, California • Atlanta, Georgia
- Conditions
- Fatty Liver, Insulin Resistance
- Interventions
- rosiglitazone, fenofibrate, placebo for rosiglitazone, placebo for fenofibrate
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Interventions
- Efinopegdutide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more